Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 42 homolog (ZFP42, also known as Rex1) is a DNA-binding transcription factor characterized by zinc finger motifs. It is expressed primarily in undifferentiated embryonic stem cells, germ cells, and some adult tissues. ZFP42 plays a critical role in maintaining pluripotency and suppressing differentiation, as its expression is downregulated upon induction of differentiation (e.g., retinoic acid treatment). It is involved in reprogramming X-chromosome inactivation during acquisition of pluripotency and efficient elongation of the noncoding RNA TSIX. Although implicated in cell proliferation, cell cycle regulation, and development, including gonad development and neuronal/vascular differentiation, ZFP42 is not currently considered a direct therapeutic target, nor are there drugs that modulate its activity. Its primary utility is as a molecular marker for pluripotent stem cell characterization and research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 42 homolog (ZFP42).